Maximum quantity allowed is 999
请选择数量
CAS RN: 231277-92-2 | 产品编码: L0360
Lapatinib
×
![]()
×
纯度/分析方法: >98.0%(T)(HPLC)
别名：
- 拉帕替尼
- N-[3-氯-4-[(3-氟苄基)氧基]苯基]-6-[5-[[(2-(甲磺酰基)乙基]氨基]甲基]呋喃-2-基]喹唑啉-4-胺
- N-[3-氯-4-[(3-氟苄基)氧基]苯基]-6-[5-[[[2-(甲磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-氨基喹唑啉
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
产品文档：
| 产品编码 | L0360 |
纯度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式/分子量 | C__2__9H__2__6ClFN__4O__4S = 581.06 |
| 外观与形状（20°C） | 固体 |
| 储存温度
|
冷藏 (0-10°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| 包装和容器
|
1G-Glass Bottle with Plastic Insert （查看图片）, 250MG-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 231277-92-2 |
| Reaxys-RN | 10502247 |
| PubChem物质ID | 468592164 |
| MDL编号 | MFCD09264194 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 145.0 to 149.0 °C |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 147 °C |
| 最大吸收波长 | 367 nm (MeOH) |
GHS
| 危险性说明 | H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
相关法规
| RTECS# | VA0952500 |
运输信息
| HS编码* | 2934.99-000 |
应用
Lapatinib: A Dual Kinase Inhibitor of EGFR and HER2
Lapatinib (GW572016) is a 4-anilinoquinazoline dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. Advanced breast cancer or metastatic breast cancer often overexpress HER2 which is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Lapatinib plus capecitabine [C2878] (a prodrug of 5-FU [F0151]) has shown potent activity in solid tumors, with the most notable in advanced or metastatic breast cancer. (The product is for research purpose only.)
References
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases (a review)
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer (a review)
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。